Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study
et al., Advanced Biomedical Research, doi:10.4103/abr.abr_104_21, IRCT20200414047076N1
, Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis.., Advanced Biomedical Research, doi:10.4103/abr.abr_104_21, IRCT20200414047076N1
RCT 143 healthcare workers in Iran, showing lower cases with HCQ prophylaxis, statistically significant only for moderate/severe cases. Baseline details are not provided.
|
risk of symptomatic case, 92.2% lower, RR 0.08, p = 0.03, treatment 0 of 70 (0.0%), control 6 of 73 (8.2%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), severe cases.
|
|
risk of symptomatic case, 85.1% lower, RR 0.15, p = 0.003, treatment 2 of 70 (2.9%), control 14 of 73 (19.2%), NNT 6.1, moderate or severe cases.
|
|
risk of symptomatic case, 47.9% lower, RR 0.52, p = 0.16, treatment 7 of 70 (10.0%), control 14 of 73 (19.2%), NNT 11, all cases.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Nasri et al., 27 Jan 2023, Randomized Controlled Trial, Iran, peer-reviewed, mean age 29.7, 11 authors, study period 11 August, 2020 - 11 November, 2020, trial IRCT20200414047076N1.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.